Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

FGF21 targets pathways which enhance insulin sensitivity in brown adipose but not skeletal muscle in mice

Juber MC., King-McAlpin S., Buscaglia P., Sebag JA., Potthoff MJ.

Animal Study on Type 2 Diabetes, published in Endocrinology (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Endocrinology (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41926710
PMCID
PMC13098676
DOI
10.1210/endocr/bqag040

Abstract (original English)

Acute pharmacological administration of the endocrine hormone fibroblast growth factor 21 (FGF21) enhances insulin sensitivity. This acute insulin-sensitizing effect of FGF21 is mediated through direct signaling to brown adipose tissues. Since skeletal muscle is an important site of insulin-stimulated glucose intake and shares a common progenitor cell with brown adipocytes, we examined whether the beneficial effects of FGF21 administration could be enhanced by making skeletal muscle a FGF21-responsive target tissue. This was accomplished by ectopically expressing the FGF21 co-receptor, β-klotho, in skeletal muscle. Here, we demonstrate that under normal conditions, FGF21 does not enhance insulin-stimulated glucose uptake in skeletal muscle. In addition, generation of FGF21 responsiveness and direct signaling to skeletal muscle also has no effect on FGF21-mediated increases in whole-body or skeletal muscle insulin sensitivity. Instead, FGF21 uniquely signals to brown adipocytes to enhance insulin-stimulated glucose uptake. Therefore, to identify how FGF21 signals to brown adipocytes to enhance insulin sensitivity, we performed comprehensive phospho-proteomics in brown adipocytes in response to FGF21 and/or insulin. Our results indicate that FGF21 administration increases the phosphorylation of several proteins involved in the trafficking of GLUT4 in primary brown adipocytes. The

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Muscle, SkeletalAnimalsMice, Inbred C57BLMiceInsulin ResistanceInsulinGlucoseFibroblast Growth FactorsMembrane ProteinsSignal Transduction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research